Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Parkinson's Disease

  Free Subscription

Articles published in Exp Neurol

Retrieve available abstracts of 66 articles:
HTML format

Single Articles

    April 2021
  1. LANGLEY MONICA R, Shivani G, Ay Muhammet PBN, Huajun J, et al
    Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Exp Neurol. 2021 Apr 8:113716. doi: 10.1016/j.expneurol.2021.113716.
    PubMed     Abstract available

    March 2021
  2. BECKSTEAD MJ, Howell RD
    Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Exp Neurol. 2021 Mar 19:113707. doi: 10.1016/j.expneurol.2021.113707.
    PubMed     Abstract available

  3. BERGKVIST L, Johnson ME, Mercado G, Steiner JA, et al
    An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
    Exp Neurol. 2021 Mar 13:113693. doi: 10.1016/j.expneurol.2021.113693.
    PubMed     Abstract available

    January 2021
  4. MCKNIGHT I, Hart C, Park IH, Shim JW, et al
    Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
    Exp Neurol. 2021;335:113523.
    PubMed     Abstract available

    December 2020
  5. SIMMNACHER K, Krach F, Schneider Y, Alecu JE, et al
    Unique signatures of stress-induced senescent human astrocytes.
    Exp Neurol. 2020;334:113466.
    PubMed     Abstract available

    November 2020
  6. SI XL, Fang YJ, Li LF, Gu LY, et al
    From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
    Exp Neurol. 2020 Nov 5:113525. doi: 10.1016/j.expneurol.2020.113525.
    PubMed     Abstract available

    October 2020
  7. HAUMESSER JK, Beck MH, Pellegrini F, Kuhn J, et al
    Subthalamic beta oscillations correlate with dopaminergic degeneration in experimental parkinsonism.
    Exp Neurol. 2020;335:113513.
    PubMed     Abstract available

  8. SCHNEIDER JS, Marshall CA, Keibel L, Snyder NW, et al
    A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Exp Neurol. 2020;335:113514.
    PubMed     Abstract available

    July 2020
  9. WANG Y, Bouabid S, Darvas M, Zhou FM, et al
    The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Exp Neurol. 2020 Jul 28:113427. doi: 10.1016/j.expneurol.2020.113427.
    PubMed     Abstract available

    May 2020
  10. CINAR E, Yalcin-Cakmakli G, Saka E, Ulusoy A, et al
    Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Exp Neurol. 2020 May 10:113357. doi: 10.1016/j.expneurol.2020.113357.
    PubMed     Abstract available

    April 2020
  11. HAQUE A, Samantaray S, Knaryan VH, Capone M, et al
    Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.
    Exp Neurol. 2020 Apr 14:113315. doi: 10.1016/j.expneurol.2020.113315.
    PubMed     Abstract available

    March 2020
  12. WU G, Lu ZH, Seo JH, Alselehdar SK, et al
    Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
    Exp Neurol. 2020 Mar 9:113284. doi: 10.1016/j.expneurol.2020.113284.
    PubMed     Abstract available

    December 2019
  13. KOUTZOUMIS DN, Vergara M, Pino J, Buddendorff J, et al
    Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease.
    Exp Neurol. 2019;325:113159.
    PubMed     Abstract available

    November 2019
  14. OLIVEIRA LM, Henrique E, Bustelli IB, Netto NFC, et al
    Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model.
    Exp Neurol. 2019;323:113110.
    PubMed     Abstract available

  15. RAUSCHENBERGER L, Knorr S, Al-Zuraiqi Y, Tovote P, et al
    Striatal dopaminergic dysregulation and dystonia-like movements induced by sensorimotor stress in a pharmacological mouse model of rapid-onset dystonia-parkinsonism.
    Exp Neurol. 2019;323:113109.
    PubMed     Abstract available

    September 2019
  16. ZHANG J, Lv S, Tang G, Bian G, et al
    Activation of calcium-impermeable GluR2-containing AMPA receptors in the lateral habenula produces antidepressant-like effects in a rodent model of Parkinson's disease.
    Exp Neurol. 2019;322:113058.
    PubMed     Abstract available

    April 2019
  17. CAMPOS ACP, Berzuino MB, Hernandes MS, Fonoff ET, et al
    Monoaminergic regulation of nociceptive circuitry in a Parkinson's disease rat model.
    Exp Neurol. 2019;318:12-21.
    PubMed     Abstract available

    March 2019
  18. TUCKER H, Mahoney E, Chhetri A, Unger K, et al
    Deep brain stimulation of the ventroanterior and ventrolateral thalamus improves motor function in a rat model of Parkinson's disease.
    Exp Neurol. 2019 Mar 16. pii: S0014-4886(19)30045.
    PubMed     Abstract available

    February 2019
  19. BULBUL M, Sinen O, Ozkan A, Aslan MA, et al
    Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats.
    Exp Neurol. 2019;317:78-86.
    PubMed     Abstract available

  20. DOMENICI RA, Campos ACP, Maciel ST, Berzuino MB, et al
    Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion.
    Exp Neurol. 2019;315:72-81.
    PubMed     Abstract available

    October 2018
  21. GIL-TOMMEE C, Vidal-Martinez G, Annette Reyes C, Vargas-Medrano J, et al
    Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder.
    Exp Neurol. 2018;311:265-273.
    PubMed     Abstract available

    September 2018
  22. COOPER JF, Spielbauer KK, Senchuk MM, Nadarajan S, et al
    alpha-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
    Exp Neurol. 2018 Sep 5. pii: S0014-4886(18)30432.
    PubMed     Abstract available

    August 2018
  23. OLIVEIRA LM, Falquetto B, Moreira TS, Takakura AC, et al
    Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson's disease model.
    Exp Neurol. 2018;309:107-118.
    PubMed     Abstract available

  24. CHENG S, Tereshchenko J, Zimmer V, Vachey G, et al
    Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Exp Neurol. 2018;309:79-90.
    PubMed     Abstract available

  25. WU S, Lei L, Song Y, Liu M, et al
    Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.
    Exp Neurol. 2018;309:67-78.
    PubMed     Abstract available

    July 2018
  26. HOSSAIN MM, Weig B, Reuhl K, Gearing M, et al
    The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6.
    Exp Neurol. 2018;308:111-119.
    PubMed     Abstract available

    June 2018
  27. ZHANG Z, Shen Y, Luo H, Zhang F, et al
    MANF protects dopamine neurons and locomotion defects from a human alpha-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways.
    Exp Neurol. 2018 Jun 27. pii: S0014-4886(18)30206.
    PubMed     Abstract available

    May 2018
  28. DU TT, Chen YC, Lu YQ, Meng FG, et al
    Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
    Exp Neurol. 2018 May 21. pii: S0014-4886(18)30127.
    PubMed     Abstract available

    April 2018
  29. EKIMOVA IV, Plaksina DV, Pastukhov YF, Lapshina KV, et al
    New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease.
    Exp Neurol. 2018 Apr 25. pii: S0014-4886(18)30099.
    PubMed     Abstract available

    March 2018
  30. ROUILLARD C, Baillargeon J, Paquet B, St-Hilaire M, et al
    Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2018 Mar 9. pii: S0014-4886(18)30070.
    PubMed     Abstract available

    February 2018
  31. SUN X, Aime P, Dai D, Ramalingam N, et al
    Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
    Exp Neurol. 2018 Feb 9. pii: S0014-4886(18)30022.
    PubMed     Abstract available

    January 2018
  32. REN M, Guo Y, Wei X, Yan S, et al
    TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
    Exp Neurol. 2018;302:205-213.
    PubMed     Abstract available

  33. YU Q, Huang Q, Du X, Xu S, et al
    Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
    Exp Neurol. 2018 Jan 11. pii: S0014-4886(18)30016.
    PubMed     Abstract available

  34. LIMA JC, Oliveira LM, Botelho MT, Moreira TS, et al
    The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease.
    Exp Neurol. 2018 Jan 3. pii: S0014-4886(18)30003.
    PubMed     Abstract available

    December 2017
  35. GALATI S, Song W, Orban G, Luft AR, et al
    Cortical slow wave activity correlates with striatal synaptic strength in normal but not in Parkinsonian rats.
    Exp Neurol. 2017;301.
    PubMed     Abstract available

  36. CENCI MA, Olanow CW
    Translating scientific advances into disease-modifying therapies for Parkinson's Disease.
    Exp Neurol. 2017;298.

  37. BRUNDIN P, Dave KD, Kordower JH
    Therapeutic approaches to target alpha-synuclein pathology.
    Exp Neurol. 2017;298.
    PubMed     Abstract available

  38. SMITH L, Mullin S, Schapira AHV
    Insights into the structural biology of Gaucher disease.
    Exp Neurol. 2017;298.
    PubMed     Abstract available

  39. OLANOW CW, Kieburtz K, Katz R
    Clinical approaches to the development of a neuroprotective therapy for PD.
    Exp Neurol. 2017;298.
    PubMed     Abstract available

    November 2017
  40. BONATO JM, Bassani TB, Milani H, Vital MA, et al
    Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
    Exp Neurol. 2017 Nov 18. pii: S0014-4886(17)30323.
    PubMed     Abstract available

  41. HARMS AS, Thome AD, Yan Z, Schonhoff AM, et al
    Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.
    Exp Neurol. 2017;300:179-187.
    PubMed     Abstract available

  42. WANG YY, Wang Y, Jiang HF, Liu JH, et al
    Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats.
    Exp Neurol. 2017;300:135-148.
    PubMed     Abstract available

  43. CHAO H, Liu Y, Fu X, Xu X, et al
    Lowered iPLA2gamma activity causes increased mitochondrial lipid peroxidation and mitochondrial dysfunction in a rotenone-induced model of Parkinson's disease.
    Exp Neurol. 2017 Nov 2. pii: S0014-4886(17)30291.
    PubMed     Abstract available

    October 2017
  44. FRANCARDO V, Schmitz Y, Sulzer D, Angela Cenci M, et al
    Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
    Exp Neurol. 2017 Oct 5. pii: S0014-4886(17)30243.
    PubMed     Abstract available

  45. BLESA J, Trigo-Damas I, Dileone M, Del Rey NL, et al
    Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification.
    Exp Neurol. 2017 Oct 4. pii: S0014-4886(17)30244.
    PubMed     Abstract available

    September 2017
  46. KUHN J, Haumesser JK, Beck MH, Altschuler J, et al
    Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
    Exp Neurol. 2017 Sep 8. pii: S0014-4886(17)30235.
    PubMed     Abstract available

    August 2017
  47. JAMES SURMEIER D, Halliday GM, Simuni T
    Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
    Exp Neurol. 2017 Aug 2. pii: S0014-4886(17)30206.
    PubMed     Abstract available

    July 2017
  48. WEST AB
    Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30203.
    PubMed     Abstract available

  49. KO WKD, Bezard E
    Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to alpha-synuclein targeted disease modification.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30202.
    PubMed     Abstract available

  50. FISCHER P, Pogosyan A, Cheeran B, Green AL, et al
    Subthalamic nucleus beta and gamma activity is modulated depending on the level of imagined grip force.
    Exp Neurol. 2017;293:53-61.
    PubMed     Abstract available

    June 2017
  51. CROTTY GF, Ascherio A, Schwarzschild MA
    Targeting urate to reduce oxidative stress in Parkinson disease.
    Exp Neurol. 2017 Jun 13. pii: S0014-4886(17)30157.
    PubMed     Abstract available

  52. MEADOWS SM, Chambers NE, Conti MM, Bossert SC, et al
    Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
    Exp Neurol. 2017;292:168-178.
    PubMed     Abstract available

    May 2017
  53. MOREIRA S, Fonseca I, Nunes MJ, Rosa A, et al
    Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease.
    Exp Neurol. 2017 May 25. pii: S0014-4886(17)30126.
    PubMed     Abstract available

  54. LAZARO DF, Pavlou MAS, Outeiro TF
    Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.
    Exp Neurol. 2017 May 16. pii: S0014-4886(17)30124.
    PubMed     Abstract available

    April 2017
  55. SCOTT L, Dawson VL, Dawson TM
    Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30102.
    PubMed     Abstract available

  56. ALAM M, Rumpel R, Jin X, von Wrangel C, et al
    Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30101.
    PubMed     Abstract available

  57. OLIVEIRA LM, Tuppy M, Moreira TS, Takakura AC, et al
    Role of the locus coeruleus catecholaminergic neurons in the chemosensory control of breathing in a Parkinson's disease model.
    Exp Neurol. 2017;293:172-180.
    PubMed     Abstract available

    March 2017
  58. BIMPISIDIS Z, M Oberg C, Maslava N, Cenci MA, et al
    Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
    Exp Neurol. 2017 Mar 8. pii: S0014-4886(17)30066.
    PubMed     Abstract available

    February 2017
  59. MONNOT C, Zhang X, Nikkhou-Aski S, Damberg P, et al
    Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
    Exp Neurol. 2017 Feb 18. pii: S0014-4886(17)30048.
    PubMed     Abstract available

    January 2017
  60. FRAU R, Savoia P, Fanni S, Fiorentini C, et al
    The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2017;291:1-7.
    PubMed     Abstract available

  61. HAO F, Yang C, Chen SS, Wang YY, et al
    Long-Term Protective Effects of AAV9-Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene Transfer in Parkinsonian Rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30016.
    PubMed     Abstract available

  62. FJODOROVA M, Torres EM, Dunnett SB
    Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30019.
    PubMed     Abstract available

    December 2016
  63. BENTEA E, Van Liefferinge J, Verbruggen L, Martens K, et al
    Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc.
    Exp Neurol. 2016 Dec 23. pii: S0014-4886(16)30418.
    PubMed     Abstract available

    October 2016
  64. BECK MH, Haumesser JK, Kuhn J, Altschuler J, et al
    Short- and long-term dopamine depletion causes enhanced beta oscillations in the cortico-basal ganglia loop of parkinsonian rats.
    Exp Neurol. 2016;286:124-136.
    PubMed     Abstract available

    September 2016
  65. MULAS G, Espa E, Fenu S, Spiga S, et al
    Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Exp Neurol. 2016 Sep 30. pii: S0014-4886(16)30299.
    PubMed     Abstract available

  66. WU Q, Yang X, Zhang Y, Zhang L, et al
    Chronic mild stress accelerates the progression of Parkinson's disease in A53T alpha-synuclein transgenic mice.
    Exp Neurol. 2016;285.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.